Literature DB >> 26957614

Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic.

Siu-Fun Wong1, Mark Bounthavong2, Cham P Nguyen3, Timothy Chen4.   

Abstract

BACKGROUND: Increasing use of oral chemotherapy drugs increases the challenges for drug and patient management. An oral chemotherapy management clinic was developed to provide patients with oral chemotherapy management, concurrent medication (CM) education, and symptom management services. This evaluation aims to measure the need and effectiveness of this practice model due to scarce published data.
METHODS: This is a case series report of all patients referred to the oral chemotherapy management clinic. Data collected included patient demographics, depression scores, CMs, and types of intervention, including detection and management outcomes collected at baseline, 3-day, 7-day, and 3-month follow-ups. Persistence rate was monitored. Secondary analysis assessed potential cost avoidance.
RESULTS: A total of 86 evaluated patients (32 men and 54 women, mean age of 63.4 years) did not show a high risk for medication nonadherence. The 3 most common cancer diagnoses were rectal, pancreatic, and breast, with capecitabine most prescribed. Patients had an average of 13.7 CMs. A total of 125 interventions (detection and management of adverse drug event detection, compliance, drug interactions, medication error, and symptom management) occurred in 201 visits, with more than 75% of interventions occurring within the first 14 days. A persistence rate was observed in 78% of 41 evaluable patients. The total estimated annual cost avoidance per 1.0 full time employee (FTE) was $125,761.93.
CONCLUSIONS: This evaluation demonstrated the need for additional support for patients receiving oral chemotherapy within standard of care medical service. A comprehensive oral chemotherapy management referral service can optimize patient care delivery via early interventions for adverse drug events, drug interactions, and medication errors up to 3 months after initiation of treatment.
Copyright © 2016 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26957614     DOI: 10.6004/jnccn.2016.0033

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  9 in total

1.  Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review.

Authors:  Shoshana M Rosenberg; Keith J Petrie; Annette L Stanton; Lan Ngo; Emma Finnerty; Ann H Partridge
Journal:  J Natl Cancer Inst       Date:  2020-05-01       Impact factor: 13.506

2.  Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis.

Authors:  Reka Pataky; David A Tran; Andrea Coronado; Riaz Alvi; Darryl Boehm; Dean A Regier; Stuart Peacock
Journal:  CMAJ Open       Date:  2018-07-27

3.  Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM).

Authors:  A Santaballa; J De Castro; J Maurel; M Lázaro; R Vera; E Alba
Journal:  Clin Transl Oncol       Date:  2018-10-16       Impact factor: 3.405

4.  Clinical Pharmacy Services in Ambulatory Oncology: An Environmental Scan of the Canadian Practice Landscape.

Authors:  Bryanna Tibensky; Lauren Hutton; Jason Wentzell; Michael LeBlanc; Scott Edwards; Thomas McFarlane
Journal:  Can J Hosp Pharm       Date:  2022-10-03

5.  Fabrication Of Dual pH/redox-Responsive Lipid-Polymer Hybrid Nanoparticles For Anticancer Drug Delivery And Controlled Release.

Authors:  Wanfu Men; Peiyao Zhu; Siyuan Dong; Wenke Liu; Kun Zhou; Yu Bai; Xiangli Liu; Shulei Gong; Can Yang Zhang; Shuguang Zhang
Journal:  Int J Nanomedicine       Date:  2019-10-03

6.  A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial.

Authors:  Marco Egbring; Elmira Far; Malgorzata Roos; Michael Dietrich; Mathis Brauchbar; Gerd A Kullak-Ublick; Andreas Trojan
Journal:  J Med Internet Res       Date:  2016-09-06       Impact factor: 5.428

7.  Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy.

Authors:  Lauren A Marcath; Colin M Finley; Siu Fun Wong; Daniel L Hertz
Journal:  BMC Cancer       Date:  2021-03-26       Impact factor: 4.430

8.  Effects of financial toxicity on prescription drug use and mental well-being in cancer patients.

Authors:  Kelly Chan; Aryana Sepassi; Ila M Saunders; Aaron Goodman; Jonathan H Watanabe
Journal:  Explor Res Clin Soc Pharm       Date:  2022-04-14

9.  Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews.

Authors:  Richard H Parrish; Heather Monk Bodenstab; Dustin Carneal; Ryan M Cassity; William E Dager; Sara J Hyland; Jenna K Lovely; Alyssa Pollock; Tracy M Sparkes; Siu-Fun Wong
Journal:  J Clin Med       Date:  2022-09-24       Impact factor: 4.964

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.